Ozurdex dexamethasone intravitreal implant regulatory update

The Scottish Medicines Consortium recommended against the use of Ozurdex dexamethasone intravitreal implant on the National Health Service (NHS) in Scotland to treat non-infectious uveitis affecting the posterior segment of the eye in adults because it did not receive a submission from Allergan. In December, the agency recommended against Ozurdex to treat macular edema following either branch retinal vein occlusion (BRVO) or central vein occlusion (CRVO) in adults because it said Allergan did not present sufficient clinical and economic analysis (see BioCentury, Jan. 2). ...